Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.36 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29812039 | 1.00 | CA12 (0.49) | CA12CA1CA2CA9CA14 | |
| SCHEMBL23143854 | 0.87 | CA2 (0.61) | CA12CA1CA2CA9CA14 | |
| SCHEMBL23144126 | 0.84 | CA12 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL23144110 | 0.83 | PDK1 (0.46) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL30871243 | 0.83 | CA1 (0.44) | CA12CA1CA2CA9ALDH3A1 | |
| SCHEMBL23144748 | 0.80 | TOP2B (0.48) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL29212406 | 0.80 | CA12 (0.42) | CA12CA1CA2CA9CA14 | |
| SCHEMBL23143977 | 0.79 | LRRK2 (0.42) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL31363348 | 0.79 | CA12 (0.41) | CA12CA1CA2CA9CA14 | |
| SCHEMBL25033217 | 0.79 | CA12 (0.41) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4644387-A2 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| EP-4469043-A2 | DEUTERATED COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118891041-A | Deuterated compounds for restoring mutant p53 function | 皮姆维制药公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240342151-A1 | DEUTERATED COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2024-10-17 | — | — | US | disclosed |
| US-11963953-B2 | Deuterated compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230301975-A1 | DEUTERATED COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230301975-A1 | DEUTERATED COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2023147419-A2 | DEUTERATED COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147419-A2 | DEUTERATED COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| US-20220315564-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-115003299-A | Methods and compounds for restoring function of mutant p53 | 皮姆维制药公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-4034104-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2021061643-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021061643-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11963953-B2 | Deuterated compounds for restoring mutant p53 function | TP53, TP53BP1, MDM2 | CA12 3766/4885CA1 2602/4885CA2 4064/4885 |
| US-20240342151-A1 | DEUTERATED COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | CA12 3766/4885CA1 2602/4885CA2 4064/4885 |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-20230301975-A1 | DEUTERATED COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | CA12 3766/4885CA1 2602/4885CA2 4064/4885 |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3679/4885CA1 2747/4885CA2 3444/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | CA12 3295/4885CA1 2782/4885CA2 3601/4885 |
| US-20220315564-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA1 2828/4885CA2 3501/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | CA12 3515/4885CA1 3047/4885CA2 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.